Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 13, 2006
Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS)M H Gottesman, S Friedman-UrevichParaplegia|March 1, 1992
Modified Brown-Séquard syndrome following coronary artery bypass graft: case reportM H Gottesman, I Saraya, F TentiMultiple Sclerosis (Houndmills, Basingstoke, England)|December 10, 2009
Neutralizing antibodies to 500 microg interferon beta-1b: 28-month results of the IDEAS extension trialM H Gottesman, S Friedman-Urevich, E Boylan, et al.Headache|June 1, 1996
Cardiac arrest caused by trigeminal neuralgiaM H Gottesman, B Ibrahim, A S Elfenbein, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|September 27, 2007
Tissue plasminogen activator for acute stroke in everyday clinical practiceE J Wirkowski, M H Gottesman, C Mazer, et al.The American Surgeon|April 17, 1998
The CVC removal distress syndrome: an unappreciated complication of central venous catheter removalD K Kim, M H Gottesman, A Forero, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 1999
A profile of multiple sclerosis: the New York State Multiple Sclerosis ConsortiumL D Jacobs, K E Wende, C M Brownscheidle, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 20, 2003
Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis ConsortiumB Weinstock-Guttman, L D Jacobs, C M Brownscheidle, et al.Pageof 1